Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: Results of a large registry-based cohort analysis

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Buchler, Tomas ^a   Pavlik, Tomas ^b   Melichar, Bohuslav ^c   Bortlicek, Zbynek ^b   Usiakova, Zuzana ^d   Dusek, Ladislav ^b   Kiss, Igor ^e   Kohoutek, Milan ^f   Benesova, Vera ^g   Vyzula, Rostislav ^e   Abrahamova, Jitka ^a   Obermannova, Radka ^e  

^a CHARLES UNIVERSITY   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^f Bata Hospital   (Czech Republic)

^g Hospital Jihlava   (Czech Republic)

Author keywords

5 fluorouracil; Bevacizumab; Capecitabine; Colorectal cancer; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; CZECH REPUBLIC; DISEASE COURSE; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; REGISTER; SECONDARY; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; CZECH REPUBLIC; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84900448943     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-323     Document Type: Article

References (11)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342. 10.1056/NEJMoa032691, 15175435.
2. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019. 10.1200/JCO.2007.14.9930, 18421054.
3. Stathopoulos GP, Batziou C, Trafalis D, Koutantos J, Batzios S, Stathopoulos J, Legakis J, Armakolas A. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology 2010, 78:376-381. 10.1159/000320520, 20798560.
4. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern cooperative oncology group study E3200. J Clin Oncol 2007, 25:1539-1544. 10.1200/JCO.2006.09.6305, 17442997.
5. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T, Saltz L. First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Ann Oncol 2006, 17(9):LBA3.
6. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, Martoni A, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, Porschen R. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008, 26:5910-5917. 10.1200/JCO.2008.16.7759, 19018087.
7. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009, 20:1842-1847. 10.1093/annonc/mdp233, 19406901.
8. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009, 14:862-870. 10.1634/theoncologist.2009-0071, 19726453.
9. Meyerhardt JA, Li L, Sanoff HK, Carpenter W, Schrag D. Effectiveness of bevacizumab with first-line combination chemotherapy for medicare patients withstage IV colorectal cancer. J Clin Oncol 2012, 30:608-615. 10.1200/JCO.2011.38.9650, 3295559, 22253466.
10. Zuckerman DS, Clark JW. Systemic therapy for metastatic colorectal cancer: current questions. Cancer 2008, 112:1879-1891. 10.1002/cncr.23409, 18338815.
11. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F, Saltz L. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011, 105:58-64. 10.1038/bjc.2011.201, 3137415, 21673685.